Our key findings include 1) significant association of CYP2C19 genotype with plasma PZQ concentrations and its metabolic ratio ( trans -4-OH-PZQ/PZQ) and 2) no significant effect of CYP3A4 , CYP3A5 , CYP2C19 , and CYP2C9 genotypes on schistosomiasis treatment efficacy at 3-weeks post-treatment, 3) a borderline significant association of CYP3A5 genotype with treatment-associated adverse events, being higher among carriers of defective variant alleles (*3, *6 and *7).
← all excerpts
Effect of Pharmacogenetics Variations on Praziquantel Plasma Concentrations and Schistosomiasis Treatment Outcomes Among Infected School-Aged Children in Tanzania.
1
—
—